News about psychedelics often places very different decisions under the word “legalisation”. That simplification makes it harder to understand what has changed. Reclassifying a substance, establishing access through psychiatrists and creating licensed services do not have the same scope.
Australia and the US state of Oregon provide two useful examples. The comparison below presents the central elements of official sources and an editorial reading of the questions these models raise. It is not a recommendation to travel, undergo treatment or select a provider.
Australia: access linked to indications and authorised psychiatrists
The Therapeutic Goods Administration’s February 2023 decision created a pathway, effective from 1 July 2023, for specifically authorised psychiatrists to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression. The framework uses the Authorised Prescriber scheme. TGA — original decision.
The TGA distinguishes this access from evaluating products included in the Australian Register of Therapeutic Goods. Its consumer information describes MDMA and psilocybin among examples of unapproved products, available only in limited circumstances through healthcare practitioners. TGA — access to unapproved products.
That distinction is central. Allowing an access pathway does not mean that every available product has been assessed and approved for every use. A clinic’s article, news story or conversation with a patient should preserve this difference.
Oregon: licensed services with preparation, administration and integration
The Oregon Health Authority describes psilocybin services involving preparation, administration and integration. Access requires a minimum age of 21, preparation with a licensed facilitator and administration at a licensed service centre. A prescription or medical referral is not required to participate. OHA — what psilocybin services are.
The state explains that this is not a dispensary model: a client does not simply buy a product to take away. Consumption takes place under the authorised service’s conditions. OHA — service-centre licensing.
The state programme must also be distinguished from US federal law. Services operating in Oregon do not constitute federal approval of a medicine and do not turn the model into a psychiatric prescribing system. The phrase “regulated access” is informative only when it explains what is being regulated.
Why comparison requires more than a headline
One model organises access around indications and specialist prescribing. The other licenses services with participation and support rules. This changes the questions someone should ask: who assesses eligibility, what professional status does the person providing support have, and what is the service’s purpose?
Editorial comparison should go beyond asking which jurisdiction “went first”. Examining the participant’s pathway, the authorisation’s limits and how responsibilities are communicated is more useful. The chosen words — patient, client, treatment or service — may also reflect different frameworks.
What regulatory openings allow us to investigate
New frameworks create opportunities to observe services outside small, highly selected trials. As a public-policy reflection, outcomes, negative experiences, continuity of care and unequal access would be important to follow. Authorising an activity does not itself answer those questions.
Cost deserves attention within that analysis. Legal access may coexist with substantial financial barriers. Evaluating a model should ask not only how many people participated, but who was excluded and why. Discussion of innovation needs to consider the distribution of potential benefits and burdens.
Understanding how complaints are received and lessons drawn from incidents would also be useful. A programme becomes more transparent when it publishes information that enables its operation to be assessed, rather than favourable accounts alone. These are proposed comparison criteria, not claims that both systems already measure every dimension.
Relevance to the Portuguese debate
For Portugal, these experiences are analytical references, rather than transferable authorisations. Responses to people seeking care must remain grounded in the national framework and the service’s actual provision. A link to a foreign decision should inform without suggesting that identical access exists locally. The status of each substance in Portugal is described on our substances under research page.
The European debate also has its own dimension. The European Medicines Agency (EMA) discussed psychedelic development and assessment at a workshop in 2024, bringing together different stakeholders. This institutional discussion matters; it does not replace the applicable assessment and authorisation processes. Within the European Union, Czechia has allowed the medical use of psilocybin since 1 January 2026, in justified cases defined by law, after authorised medicines have failed; the framework is described in our article on law and regulation. EMA — workshop agenda.
Reading foreign decisions accurately allows possibilities to be discussed without creating false certainty. Instead of a generic announcement of “legalisation”, readers should find concrete answers: in which jurisdiction, for what purpose, through whom and under which conditions. That clarity makes international comparison useful to professionals and the public.
